FDA Approves Azurity Pharmaceuticals’ Fleqsuvy for Treating Spasticity

February 11, 2022

Azurity Pharmaceuticals’ Fleqsuvy (baclofen oral suspension, 5 mg/mL) has won FDA approval for treating spasticity caused by multiple sclerosis (MS), spinal cord injuries or other spinal cord diseases.

A potentially debilitating condition in which muscles stiffen or tighten and arrest normal range of motion, spasticity affects an estimated 67 percent of MS sufferers.

Fleqsuvy is not approved for treating patients suffering from skeletal muscle spasms caused by rheumatic disorders, which are autoimmune, inflammatory conditions.

View today's stories